Intravitreal adalimumab for refractory uveitis-related macular edema

Απλή σελίδα τεκμηρίου
dc.contributor.authorAndroudi, S.en
dc.contributor.authorTsironi, E.en
dc.contributor.authorKalogeropoulos, C.en
dc.contributor.authorTheodoridou, A.en
dc.contributor.authorBrazitikos, P.en
dc.date.accessioned2015-11-24T19:09:05Z
dc.date.available2015-11-24T19:09:05Z
dc.identifier.issn1549-4713-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/20651
dc.rightsDefault Licence-
dc.subjectAdulten
dc.subjectAnti-Inflammatory Agents/*administration & dosageen
dc.subjectAntibodies, Monoclonal/*administration & dosageen
dc.subjectAntibodies, Monoclonal, Humanizeden
dc.subjectFemaleen
dc.subjectFollow-Up Studiesen
dc.subjectHumansen
dc.subjectInjectionsen
dc.subjectMacular Edema/*drug therapy/etiologyen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectProspective Studiesen
dc.subjectRetina/drug effectsen
dc.subjectRetreatmenten
dc.subjectTomography, Optical Coherenceen
dc.subjectTumor Necrosis Factor-alpha/antagonists & inhibitorsen
dc.subjectUveitis/complications/*drug therapyen
dc.subjectVisual Acuity/drug effectsen
dc.subjectVitreous Bodyen
dc.subjectYoung Adulten
dc.titleIntravitreal adalimumab for refractory uveitis-related macular edemaen
heal.abstractOBJECTIVE: To evaluate the safety and efficacy of intravitreal adalimumab injections on refractory cystoid macular edema (CME) secondary to noninfectious uveitis. DESIGN: Prospective, noncomparative, interventional case series. PARTICIPANTS: Eight consecutive patients with controlled uveitis and chronic, refractory CME who had failed steroid treatment. INTERVENTION: Intravitreal adalimumab injections were given monthly for 3 months. MAIN OUTCOME MEASURES: Mean change in central retinal thickness (CRT) on optical coherence tomography (OCT); secondary objective was the mean change in best-corrected visual acuity (BCVA). RESULTS: Five of the eight patients completed the 6-month follow-up. For all 5 patients, the changes in BCVA from baseline to 3 months were not statistically significant (P=0.070). Similarly, the change in BCVA from baseline to 6 months was not statistically significant (P=1.0). The mean CRT at baseline was 692 microm. The changes from baseline to 3 months were not statistically significant (P=0.466); the changes from baseline to 6 months were also not statistically significant (P=0.808). We did not observe any ocular or systemic adverse effects. CONCLUSIONS: Intravitreal adalimumab showed no efficacy in improving BCVA or reducing CRT in patients with chronic uveitic macular edema.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.primary10.1016/j.ophtha.2009.12.011-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/20378179-
heal.identifier.secondaryhttp://ac.els-cdn.com/S0161642009014158/1-s2.0-S0161642009014158-main.pdf?_tid=ac28974acc4b36c6599a472e2cfefe68&acdnat=1332775403_a2264a93a717dd0775208cd825abcfa7-
heal.journalNameOphthalmologyen
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate2010-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή:
Κατεβάστε

Συλλογές

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ